

CONFERENCE PROGRAM

Saturday, January 11

- 4:30 p.m.-6:15 p.m.** **PLENARY SESSION 1: THERAPEUTIC TARGETING AND VULNERABILITIES OF RAS-DRIVEN LUNG CANCER**
Pacific Ballroom 23-24
- 4:30 p.m.-4:55 p.m. **Title to be announced**
Ferdinandos Skoulidis, The University of Texas MD Anderson Cancer Center, Houston, TX
- 4:55 p.m.-5:20 p.m. **Insights into KRAS biology to identify potential therapeutic strategies**
Chiara Ambrogio, Dana-Farber Cancer Institute, Boston, MA
- 5:20 p.m.-5:45 p.m. **Therapeutic approaches in KRAS-driven non-small cell lung cancer**
Caroline McCoach, UCSF School of Medicine, San Francisco, CA
- 5:45 p.m.-6:00 p.m. **Transcriptional subtypes resolve tumor heterogeneity and identify therapeutic vulnerabilities in lung cancer***
Jonathan Cooper, Genentech, Inc., South San Francisco, CA
- 6:00 p.m.-6:15 p.m. **The SHP2 inhibitor RMC-4630 in patients with KRAS-mutant non-small cell lung cancer: Preliminary evaluation of a first-in-man phase 1 clinical trial***
Sai-Hong Ignatius Ou, University of California Irvine, Irvine, CA
- 6:15 p.m.-6:30 p.m.** **BREAK**
Pacific Ballroom Pre-Function Area 23-26
- 6:30 p.m.-7:30 p.m.** **WELCOME REMARKS AND OPENING KEYNOTE**
Pacific Ballroom 23-24
- Welcome Remarks**
Chandra P. Belani, Chief Scientific Officer, International Association for the Study of Lung Cancer
- Early-stage drug development in the 21st century**
William Pao, Roche Innovation Center Basel, Basel, Switzerland
(not eligible for CME credit)
- 7:30 p.m.-9:30 p.m.** **OPENING RECEPTION**
Pacific Ballroom 25/26

**Short talk from proffered abstract*

CONFERENCE PROGRAM

Sunday, January 12

7:00 a.m.-8:00 a.m.	CONTINENTAL BREAKFAST Pacific Ballroom 25/26
8:00 a.m.-9:30 a.m.	PLENARY SESSION 2: LUNG PRENEOPLASIA AND EARLY DETECTION Pacific Ballroom 23-24
8:00 a.m.-8:25 a.m.	Genomic underpinnings of tumor behavior in in situ and early lung adenocarcinoma Pierre Massion, Vanderbilt-Ingram Cancer Center, Nashville, TN
8:25 a.m.-8:50 a.m.	Intercepting lung cancer by understanding premalignant changes in the airway field Jennifer E. Beane, Boston University School of Medicine, Boston, MA
8:50 a.m.-9:15 a.m.	Plasma proteomic, glycomic, and autoantibody biomarkers for lung cancer early detection Paul D. Lampe, Fred Hutchinson Cancer Research Center, Seattle, WA
9:15 a.m.-9:30 a.m.	The genome-wide mutational landscape of lung cancer in never-smokers: The Women's Health Initiative (WHI) cohort* Sitapriya Moorthi, Fred Hutchinson Cancer Research Center, Seattle, WA
9:30 a.m.-10:00 a.m.	BREAK Pacific Ballroom Pre-Function Area 23-26
10:00 a.m.-11:30 p.m.	PLENARY SESSION 3: METABOLISM Pacific Ballroom 23-24
10:00 a.m.-10:25 a.m.	Mapping mitochondrial heterogeneity in lung cancer David B. Shackelford, UCLA David Geffen School of Medicine, Los Angeles, CA
10:25 a.m.-10:50 a.m.	Identification of new therapeutic targets in non-small cell lung cancer Kathryn A. O'Donnell, UT Southwestern Medical Center, Dallas, TX
10:50 a.m.-11:15 a.m.	Novel metabolic functions for redox regulators in non-small cell lung cancer Gina M. DeNicola, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
11:15 a.m.-11:30 a.m.	Integrated proteometabolomic analysis reveals metabolic vulnerabilities in small-cell lung cancer* Antony Prabhu, H. Lee Moffitt Cancer Center, Tampa, FL

**Short talk from proffered abstract*

11:35 a.m.

POSTER SESSION A HIGHLIGHTS

Pacific Ballroom 25/26

Presenters will give a 2-minute, 1-slide teaser preview of their posters to be presented in Poster Session A.

(not eligible for CME credit)

- (A03) **Lung adenocarcinoma resident microbiome may contribute to cancer hypomethylation status**
Erin Marshall, BC Cancer Research Centre, Vancouver, BC, Canada
- (A05) **ART1, a mono-ADP-ribosyltransferase, regulates tumor-infiltrating CD8+ T cells and is highly expressed in EGFR mutated lung cancers**
Sumit Mukherjee, Weill Cornell Medicine, New York, NY
- (A06) **Tri-complex inhibitors of the oncogenic, GTP-bound form of KRASG12C overcome RTK-mediated escape mechanisms and drive tumor regressions in preclinical models of NSCLC**
Robert Nichols, Revolution Medicines, Redwood City, CA
- (A07) **The genomic landscape of SMARCA4 alterations and association with patient outcomes in lung cancer**
Adam Schoenfeld, Memorial Sloan Kettering Cancer Center, New York, NY
- (A08) **MYC-driven SCLC has unique metabolic vulnerabilities**
Sarah Wait, Huntsman Cancer Institute, Salt Lake City, UT

12:00 p.m.-2:00 p.m.

POSTER SESSION A / LUNCH

Pacific Ballroom 25/26

2:00 p.m.-4:00 p.m.

PLENARY SESSION 4: PRECISION IMMUNOTHERAPY

Pacific Ballroom 23-24

2:00 p.m.-2:25 p.m.

Role of the tumor microenvironment in sensitivity and resistance to immunostimulatory therapies in NSCLC

Kurt A. Schalper, Yale University, New Haven, CT

2:25 p.m.-2:50 p.m.

Liquid biopsy approaches for precision immuno-oncology

Valsamo K. Anagnostou, Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, MD

2:50 p.m.-3:15 p.m.

Targeting myeloid cells that define the tumor immune microenvironment in NSCLC

Thomas U. Marron, Mt. Sinai Medical Center Tisch Cancer Institute, New York, NY

CONFERENCE PROGRAM

- 3:15 p.m.-3:40 p.m. **Preclinical and translational approaches to capturing mechanisms of immunotherapy response and resistance in NSCLC**
Don L. Gibbons, The University of Texas MD Anderson Cancer Center, Houston, TX
- 3:40 p.m.-3:55 p.m. **A reservoir of tumor-specific CD8 T cells in lung cancer resides in the draining lymph node***
Nikhil Joshi, Yale University, New Haven, CT
- 4:00 p.m.-4:15 p.m. BREAK**
Pacific Ballroom Pre-Function Area 23-26
- 4:15 p.m.-6:00 p.m. PLENARY SESSION 5: TARGETING TUMOR SUPPRESSORS AND “UNDRUGGABLE” TARGETS**
Pacific Ballroom 23-24
- 4:15 p.m.-4:40 p.m. **Decoding critical targets of LKB1/STK11 in NSCLC**
Reuben J. Shaw, Salk Institute, La Jolla, CA
- 4:40 p.m.-5:05 p.m. **A new generation of anti-Myc mini-proteins as potential therapy for NSCLC**
Laura Soucek, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
- 5:05 p.m.-5:30 p.m. **Druggable vulnerabilities in therapy-resistant lung cancers**
Kris C. Wood, Duke University, Durham, NC
- 5:30 p.m.-5:45 p.m. **Blockade of myeloid suppressor cells overcomes the anti-PD-1/PD-L1 resistance in KRAS-driven and LKB1-deficient NSCLC***
Rui Li, University of California Los Angeles, Los Angeles, CA
- 5:45 p.m.-6:00 p.m. **Proteogenomic characterization reveals therapeutic vulnerabilities in lung adenocarcinoma***
Michael Gillette, Broad Institute of MIT and Harvard, Cambridge, MA

**Short talk from proffered abstract*

Monday, January 13

- 7:00 a.m.-8:00 a.m.** **CONTINENTAL BREAKFAST**
Pacific Ballroom 25/26
- 8:00 a.m.-9:30 a.m.** **PLENARY SESSION 6: CELLULAR THERAPIES, VACCINES, AND NEW IO MODALITIES**
Pacific Ballroom 23-24
- 8:00 a.m.-8:25 a.m. **A new world for lung cancer vaccines: Beyond picking a single antigen for everyone**
Edward B. Garon, University of California (UCLA), Los Angeles, CA
- 8:25 a.m.-8:50 a.m. **Evaluating the role of B cells and tertiary lymphoid structures in lung cancer development and progression**
Tullia C. Bruno, University of Pittsburgh School of Medicine, Pittsburgh, PA
- 8:50 a.m.-9:05 a.m. **Dendritic cell in situ vaccination potentiates anti-PD-1 efficacy and induces immunoediting in a murine model of NSCLC***
Ramin Salehi-Rad, University of California Los Angeles, Los Angeles, CA
- 9:05 a.m.-9:20 a.m. **N-803 plus nivolumab for advanced or metastatic non-small cell lung cancer: Update on phase II experience of combination PD1 blockade with an IL-15 superagonist***
John Wrangle, Medical University of South Carolina, Charleston, SC
- 9:30 a.m.-10:00 a.m.** **BREAK**
Pacific Ballroom Pre-Function Area 23-26
- 10:00 a.m.-12:20 p.m.** **PLENARY SESSION 7: SMALL-CELL LUNG CANCER**
Pacific Ballroom 23-24
- 10:00 a.m.-10:25 a.m. **Pan-cancer convergence to a small-cell neuroendocrine phenotype that shares susceptibilities with hematologic malignancies**
Thomas G. Graeber, University of California Los Angeles, Los Angeles, CA
- 10:25 a.m.-10:50 a.m. **ASCL1 represses a latent osteogenic program in small-cell lung cancer arising from multiple cells of origin**
Trudy G. Oliver, University of Utah Huntsman Cancer Institute, Salt Lake City, UT
- 10:50 a.m.-11:15 a.m. **Identifying chemically tractable vulnerabilities in small-cell lung cancer**
David G. McFadden, UT Southwestern Medical Center, Dallas, TX
- 11:15 a.m.-11:40 a.m. **Developing new therapies in small-cell lung cancer using parallel clinical and laboratory-based studies**
Anna Farago, Massachusetts General Hospital, Boston, MA

**Short talk from proffered abstract*

CONFERENCE PROGRAM

11:40 a.m.-12:05 p.m.	Targeting DLL3 in small-cell lung cancer with novel modalities John T. Poirier, Perlmutter Cancer Center at NYU Langone Health, New York, NY
12:05 p.m.-12:20 p.m.	Unraveling the mechanisms of small-cell lung cancer brain metastasis* Fangfei Qu, Stanford University School of Medicine, Stanford, CA
12:20 p.m.-2:00 p.m.	LUNCH ON OWN
2:00 p.m.-3:15 p.m.	PLENARY SESSION 8: METASTASIS AND TUMOR PROGRESSION Pacific Ballroom 23-24
2:00 p.m.-2:25 p.m.	Adaptive determinants of metastatic progression in lung adenocarcinoma Don X. Nguyen, Yale University School of Medicine, New Haven, CT
2:25 p.m.-2:50 p.m.	Stage-specific roles of RB constrain tumor progression, lineage fidelity, and metastasis David Feldser, University of Pennsylvania, Philadelphia, PA
2:50 p.m.-3:15 p.m.	Restoring Capicua (CIC) expression to limit lung cancer metastasis Ross A. Okimoto, University of California San Francisco, San Francisco, CA
3:20 p.m.-4:50 p.m.	Panel Discussion: What to Do about Squamous Cell? Pacific Ballroom 23-24 Panel Moderator: Trudy G. Oliver , University of Utah Huntsman Cancer Institute, Salt Lake City, UT Panelists: Eric B. Haura, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL Trudy G. Oliver Paul Paik, Memorial Sloan Kettering Cancer Center, New York, NY Kwok-Kin Wong, New York University Langone Medical Center, New York, NY Targeting glucose reliance in lung squamous cell carcinoma* Jung-whan Kim, University of Texas at Dallas, Richardson, TX
4:55 p.m.	POSTER SESSION B HIGHLIGHTS Pacific Ballroom 25/26 <i>Presenters will give a 2-minute, 1-slide teaser preview of their posters to be presented in Poster Session B.</i> (not eligible for CME credit)
(B01)	Active YAP as a functional marker of drug-tolerant persister cells in EGFR-mutant and ALK fusion-positive NSCLC Franziska Haderk, University of California San Francisco, San Francisco, CA

*Short talk from proffered abstract

- (B02) **The GSK3 signaling axis regulates adaptive glutamine metabolism in lung squamous cell carcinoma**
Milica Momcilovic, University of California Los Angeles, Los Angeles, CA
- (B03) **JNJ-61186372, an Fc effector enhanced EGFR/cMet bispecific antibody, induces EGFR/cMet downmodulation and efficacy through monocyte and macrophage trogocytosis**
Sheri Moores, Janssen Research & Development, Spring House, PA
- (B04) **Integrative approach to map the tumor suppressor landscape of small-cell lung cancer genome**
Kwon-Sik Park, University of Virginia, Charlottesville, VA
- (B05) **Identifying SCLC vulnerabilities using phenotypic chemical screens**
Juan Manuel Povedano Selfa, University of Texas Southwestern Medical Center, Dallas, TX
- (B06) **Time-resolved RNA-seq identifies transient gene expression changes following initial chemotherapy challenge in small-cell lung cancer**
David Shia, University of California Los Angeles, Los Angeles, CA
- (B07) **Mechanisms of alectinib resistance in a leptomeningeal carcinomatosis of EML4-ALK lung cancer and its circumvention by EGR-TKIs**
Seiji Yano, Kanazawa University, Kanazawa, Ishikawa, Japan

5:15 p.m.-7:15 p.m.

POSTER SESSION B / RECEPTION

Pacific Ballroom 25/26

Tuesday, January 14

7:00 a.m.-8:00 a.m.

CONTINENTAL BREAKFAST

Pacific Ballroom 25/26

8:00 a.m.-10:00 a.m.

PLENARY SESSION 9: GENOMIC MECHANISMS OF RESISTANCE

Pacific Ballroom 23-24

8:00 a.m.-8:25 a.m.

Title to be announced

Robert C. Doebele, University of Colorado Denver, Aurora, CO

8:25 a.m.-8:50 a.m.

Title to be announced

Zofia Piotrowska, Massachusetts General Hospital, Boston, MA

CONFERENCE PROGRAM

8:50 a.m.-9:15 a.m.	Investigating and overcoming primary resistance of EGFR and HER2 (ERBB2) exon 20 mutant NSCLC Jacqulyne Robichaux, The University of Texas MD Anderson Cancer Center, Houston, TX
9:15 a.m.-9:35 a.m.	Genetic contributors to tumor progression and drug resistance in EGFR mutant lung cancer Katerina A. Politi, Yale Cancer Center, New Haven, CT
9:35 a.m.-9:45 a.m.	Advocate presentation Jill Feldman, Co-Founder, EGFR Resisters
9:45 a.m.-9:55 a.m.	Advocate presentation Janet Freeman-Daily, Co-Founder, The ROS1ders
10:00 a.m.-10:30 a.m.	BREAK Pacific Ballroom Pre-Function Area 23-26
10:30 a.m.-12:15 p.m.	PLENARY SESSION 10: NONGENETIC MECHANISMS OF RESISTANCE Pacific Ballroom 23-24
10:30 a.m.-10:55 a.m.	Nongenetic mechanisms of resistance Trever G. Bivona, University of California San Francisco, San Francisco, CA
10:55 a.m.-11:20 a.m.	Mechanisms of small-cell lineage transformation in resistance to targeted therapies William W. Lockwood, British Columbia Cancer Agency, Vancouver, BC, Canada
11:20 a.m.-11:45 a.m.	The YAP/FOXM1 axis regulates EMT-associated EGFR tyrosine kinase inhibitor resistance and increased expression of spindle assembly checkpoint components John V. Heymach, The University of Texas MD Anderson Cancer Center, Houston, TX
11:45 a.m.-12:05 p.m.	Bypass signaling pathways that confer resistance to EGFR and ALK inhibitors Christine M. Lovly, Vanderbilt University School of Medicine, Nashville, TN
12:05 p.m.-12:15 p.m.	Advocate presentation Colin Barton, Executive Board Member, ALK Positive